mediwound
completes
enrollment
stage
nexobrid
phase
pediatric
study
yavne
israel
globe
newswire
mediwound
nasdaq
mdwd
biopharmaceutical
company
bringing
innovative
therapies
address
unmet
needs
severe
burn
wound
management
today
announced
completed
enrollment
stage
phase
pediatric
clinical
study
cids
children
innovation
debridement
study
results
months
follow
data
anticipated
second
half
additionally
completion
cids
enrollment
stage
follows
food
drug
administration
fda
recent
agreement
allow
nexobrid
expanded
access
next
protocol
expanded
include
pediatric
well
adult
burn
patients
pleased
complete
enrollment
stage
nexobrid
pediatric
phase
study
one
comprehensive
randomized
controlled
studies
ever
conducted
pediatric
burn
patients
said
sharon
malka
chief
executive
officer
mediwound
current
mode
pediatric
burn
management
requires
intensive
medical
therapy
poses
challenges
due
surgical
complexities
treating
young
patients
severe
burns
nexobrid
option
provides
minimally
invasive
alternative
current
surgical
standard
care
treating
severe
burns
pediatric
patients
look
forward
generating
results
expand
enrollment
ongoing
next
protocol
also
include
pediatric
nick
colangelo
president
ceo
vericel
added
completing
enrollment
stage
cids
study
important
step
toward
goal
providing
nexobrid
treatment
option
pediatric
patients
severe
burns
given
nexobrid
potential
address
unique
challenges
treating
children
severe
cids
phase
multicenter
multinational
prospective
controlled
study
patients
aged
years
randomized
treated
either
nexobrid
periods
months
months
study
objectives
evaluate
efficacy
safety
nexobrid
compared
hospitalized
children
severe
thermal
burns
percent
percent
total
body
surface
area
tbsa
study
conducted
primarily
europe
accordance
design
study
protocol
endorsed
european
medicines
agency
ema
fda
study
design
includes
two
stages
data
analysis
upon
data
collection
anticipated
second
half
upon
data
collection
anticipated
second
half
study
fully
funded
biomedical
advance
research
development
authority
barda
part
office
assistant
secretary
preparedness
response
aspr
department
health
human
services
hhs
ongoing
next
protocol
supported
funded
barda
enables
continued
clinical
use
nexobrid
patients
review
nexobrid
biologics
license
application
bla
next
treatment
protocol
allows
treatment
burn
patients
deep
partial
thermal
burns
percent
total
body
surface
area
next
designed
consistent
current
burn
treatment
practices
burn
centers
anticipated
participate
inclusion
pediatric
patients
next
protocol
allow
additional
physicians
expand
experience
nexobrid
pediatric
patients
ensure
burn
care
preparedness
expand
national
capacity
trained
physicians
available
treat
patients
nexobrid
emergency
potential
approval
product
pediatric
use
nexobrid
nexobrid
concentrate
proteolytic
enzymes
enriched
bromelain
topically
administered
biological
product
enzymatically
removes
nonviable
burn
tissue
eschar
patients
deep
partial
thermal
burns
within
four
hours
application
without
harming
viable
tissue
nexobrid
approved
european
union
international
markets
designated
orphan
biologic
drug
united
states
european
union
international
markets
vericel
holds
exclusive
license
north
american
commercial
rights
nexobrid
january
mediwound
announced
positive
results
acute
phase
pivotal
phase
clinical
study
detect
nexobrid
adult
patients
deep
thermal
burns
percent
total
body
surface
area
study
met
primary
endpoint
complete
eschar
removal
compared
gel
vehicle
well
secondary
endpoints
compared
standard
care
soc
including
shorter
time
eschar
removal
lower
incidence
surgical
eschar
removal
lower
blood
loss
eschar
removal
safety
endpoints
including
key
safety
endpoint
time
complete
wound
closure
compared
patients
treated
soc
also
achieved
addition
safety
data
cosmesis
function
found
comparable
treatment
soc
arms
new
safety
signals
observed
september
fda
accepted
review
nexobrid
bla
eschar
removal
debridement
adults
deep
thermal
burns
assigned
prescription
drug
user
fee
act
pdufa
target
date
june
additional
long
term
safety
follow
data
submitted
safety
labeling
update
part
commitment
nexobrid
currently
investigational
product
united
states
mediwound
mediwound
biopharmaceutical
company
focused
developing
manufacturing
commercializing
novel
therapeutics
based
patented
proteolytic
enzyme
technology
address
unmet
needs
fields
severe
burns
chronic
wounds
mediwound
first
innovative
biopharmaceutical
product
nexobrid
rapidly
removes
burn
eschar
without
harming
viable
tissue
product
received
marketing
authorization
european
medicines
agency
well
israeli
argentinian
south
korean
russian
peruvian
ministries
health
eschar
removal
debridement
adults
deep
thermal
burns
june
biological
license
application
bla
submitted
fda
mediwound
second
innovative
product
topical
biological
drug
candidate
debridement
chronic
wounds
using
proteolytic
enzyme
technology
nexobrid
two
phase
studies
escharex
demonstrated
safety
efficacy
debridement
various
chronic
wounds
within
daily
applications
information
please
visit
barda
funding
technical
support
development
nexobrid
including
expanded
access
treatment
protocol
next
pivotal
phase
pediatric
clinical
study
cids
marketing
approval
registration
process
nexobrid
provided
biomedical
advanced
research
development
authority
barda
assistant
secretary
preparedness
response
aspr
within
department
health
human
services
hhs
ongoing
usg
contract
additional
projects
evaluation
nexobrid
funded
barda
contract
include
randomized
controlled
pivotal
clinical
trial
use
adults
population
establishment
use
data
package
development
health
economic
model
evaluate
cost
savings
impact
enable
market
adoption
united
states
information
refer
barda
cautionary
note
regarding
statements
mediwound
cautions
statements
statements
historical
fact
included
press
release
address
activities
events
developments
expect
believe
anticipate
may
occur
future
statements
although
believe
reasonable
basis
statements
contained
herein
based
current
expectations
future
events
affecting
us
subject
risks
assumptions
uncertainties
factors
difficult
predict
many
beyond
control
actual
results
may
differ
materially
expressed
implied
statements
press
release
statements
often
always
made
use
words
phrases
anticipates
intends
estimates
plans
expects
continues
believe
guidance
outlook
target
future
potential
goals
similar
words
phrases
future
conditional
verbs
would
could
may
similar
expressions
specifically
press
release
contains
statements
concerning
anticipated
progress
development
objectives
expectations
commercial
potential
nexobrid
among
factors
may
cause
results
materially
different
stated
herein
inherent
uncertainties
associated
timing
conduct
clinical
trial
product
development
activities
timing
likelihood
regulatory
approvals
timeline
data
ability
successfully
develop
commercialize
nexobrid
including
commercial
growth
potential
market
demand
product
availability
funding
barda
agreement
mediwound
use
connection
nexobrid
development
activities
competitive
developments
whether
fda
provide
marketing
approval
nexobrid
united
states
risks
related
timing
conduct
next
study
including
enrollment
pediatric
patients
impact
applicable
laws
regulations
uncertainties
associated
scope
scale
duration
impact
pandemic
specifically
pandemic
may
impact
fda
response
times
regulatory
submissions
ability
monitor
clinical
trials
conduct
necessary
reviews
inspections
may
result
timelines
materially
delayed
could
affect
development
ultimate
commercialization
nexobrid
additional
quarantines
requirements
shelter
home
incremental
mitigation
efforts
also
may
impact
ability
source
supplies
operations
ability
capacity
manufacture
sell
support
use
nexobrid
future
significant
factors
discussed
greater
detail
mediwound
annual
report
form
year
ended
december
filed
securities
exchange
commission
sec
february
quarterly
reports
form
filings
sec
statements
reflect
mediwound
current
views
date
hereof
mediwound
undertakes
specifically
disclaims
obligation
update
statements
reflect
change
respective
views
events
circumstances
occur
date
release
except
required
law
contacts
boaz
jeremy
feffer
chief
financial
officer
managing
director
lifesci
advisors
mediwound
ir
jeremy
